Biogen's Best-In-Class R&D Earn Makes It A Buy By: Benzinga via Benzinga October 17, 2017 at 11:35 AM EDT Analysts at Stifel turned bullish on Biogen Inc (NASDAQ: BIIB) for four key reasons. The firm's Thomas Shrader upgrades Biogen's stock ... Read More >> Related Stocks: Biogen Idec